Results of a multicentre randomised controlled trial of cochlear-sparing intensity-modulated radiotherapy versus conventional radiotherapy in patients with parotid cancer (COSTAR; CRUK/08/004)

PURPOSE: About 40–60% of patients treated with post-operative radiotherapy for parotid cancer experience ipsilateral sensorineural hearing loss. Intensity-modulated radiotherapy (IMRT) can reduce radiation dose to the cochlea. COSTAR, a phase III trial, investigated the role of cochlear-sparing IMRT...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Eur J Cancer
Autors principals: Nutting, Christopher M., Morden, James P., Beasley, Matthew, Bhide, Shreerang, Cook, Audrey, De Winton, Emma, Emson, Marie, Evans, Mererid, Fresco, Lydia, Gollins, Simon, Gujral, Dorothy, Harrington, Kevin, Joseph, Mano, Lemon, Catherine, Luxon, Linda, van den Blink, Qurrat, Mendes, Ruheena, Miah, Aisha, Newbold, Kate, Prestwich, Robin, Robinson, Martin, Sanghera, Paul, Simpson, Joanna, Sivaramalingam, Muthiah, Srihari, Narayanan Nair, Sydenham, Mark, Wells, Emma, Witts, Stephanie, Hall, Emma
Format: Artigo
Idioma:Inglês
Publicat: Elsevier Science Ltd 2018
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6202674/
https://ncbi.nlm.nih.gov/pubmed/30286418
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ejca.2018.08.006
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars